Dedrick, Rebekah M. http://orcid.org/0000-0002-3666-711X
Freeman, Krista G. http://orcid.org/0000-0002-2944-5076
Nguyen, Jan A.
Bahadirli-Talbott, Asli
Smith, Bailey E.
Wu, Andrew E.
Ong, Aaron S.
Lin, Cheng Ting http://orcid.org/0000-0003-0275-8037
Ruppel, Lisa C.
Parrish, Nicole M.
Hatfull, Graham F. http://orcid.org/0000-0002-6705-6821
Cohen, Keira A. http://orcid.org/0000-0002-4521-397X
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (GM131729, HL139994)
Howard Hughes Medical Institute (GT12053)
Cystic Fibrosis Foundation (HATFUL19GO)
Burroughs Wellcome Fund
Article History
Received: 10 February 2021
Accepted: 21 May 2021
First Online: 8 July 2021
Competing interests
: J.A.N. has received consulting fees from AstraZeneca. G.F.H. is a compensated consultant for Janssen. K.A.C. has received consulting fees from Insmed, Hillrom and Merck. The other authors declare no competing interests.